Belantamab mafodotin vs SENL103

NCT03525678 · Phase 2 · completed

This was a randomized but open-label phase 2 study in which all participants received belantamab mafodotin at one of two doses or formulations; there was no placebo or active comparator arm and no blinding. The primary endpoint was overall response rate by independent review, a clinical response measure, but the results are reported as per-arm rates with confidence intervals and no formal statistical comparison against a control, so the study cannot distinguish drug effect from natural history or placebo effect. The evidence is therefore descriptive phase 2 evidence of activity, not strong comparative evidence.

NCT06067581 · Phase 1 · status unknown

This is a small, uncontrolled, open-label Phase 1 dose-escalation study with no comparator arm, designed to find a safe dose of SENL103 CAR-T therapy in heavily pretreated myeloma patients. Efficacy is only a secondary measure and no results have been posted, so there is no evidence yet of a clinical effect.